Savara Inc (NASDAQ:SVRA) Receives $9.86 Average Price Target from Brokerages

Savara Inc (NASDAQ:SVRA) has been assigned an average rating of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $9.86.

Several equities analysts have commented on the company. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. HC Wainwright cut their price target on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Finally, Wells Fargo & Company initiated coverage on shares of Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 target price on the stock.

Insider Transactions at Savara

In other news, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph S. Mccracken bought 20,000 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were bought at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the transaction, the director now owns 210,837 shares in the company, valued at approximately $621,969.15. The trade was a 10.48 % increase in their position. The disclosure for this purchase can be found here. Insiders own 5.13% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SVRA. Choreo LLC purchased a new position in shares of Savara during the 2nd quarter worth about $59,000. DRW Securities LLC bought a new position in shares of Savara during the second quarter valued at approximately $62,000. Virtu Financial LLC purchased a new stake in shares of Savara in the third quarter worth approximately $67,000. Principal Financial Group Inc. raised its holdings in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after buying an additional 6,973 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of Savara by 258.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after acquiring an additional 18,534 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Stock Up 2.3 %

Shares of NASDAQ SVRA opened at $3.14 on Wednesday. The company has a market cap of $538.88 million, a price-to-earnings ratio of -7.30 and a beta of 0.92. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The firm’s fifty day moving average is $3.39 and its 200 day moving average is $3.92. Savara has a 52 week low of $2.82 and a 52 week high of $5.70.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). On average, equities research analysts expect that Savara will post -0.45 earnings per share for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.